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Background:Mutations in GNAQ/11 genes are considered an early event in the development of uveal melanoma that may derive
from a pre-existing nevus. The Hippo pathway, by way of YAP activation, rather than MAP kinase, has a role in the oncogenic
capacity of GNAQ/11 mutations.
Methods: We investigated 16 nevi from 13 human eyes for driver GNAQ/11 mutations using droplet digital PCR and determined
whether nevi are clonal by quantifying mutant nevus cell fractions. Immunohistochemistry was performed on 15 nevi to analyse
YAP activation.
Results: For 15 out of 16 nevi, a GNAQ/11 mutation was detected in the nevus cells albeit at a low frequency with a median of
13%. Nuclear YAP, a transcriptional co-activator in the Hippo tumour-suppressor pathway, was detected in 14/15 nevi.
Conclusions: Our analysis suggests that a mutation in GNAQ/11 occurs in a subset of choroidal nevus cells. We hypothesise
that GNAQ/11 mutant-driven extracellular mitogenic signalling involving YAP activation leads to accumulation of wild-type
nevus cells.
Similar to cutaneous melanoma (CM), uveal melanoma (UM) can
develop de novo or from a pre-existing nevus (Figure 1). Uveal nevi
most commonly occur in the choroid and are seen in 6.5–30% of
the population (Sumich et al, 1998; Baderca et al, 2013). However,
transformation from a choroidal nevus to a UM requires complex
genetic aberrations (gain of chromosome 8q/6p, loss of chromo-
some 3, absence of BAP1), and has been reported in only about 1
out of 9000 people (Singh et al, 2005). We hypothesise that a
choroidal nevus, as a potential precursor of UM, may already
harbour clonal driver mutations, just as many cutaneous nevi are
reported to present the typical V600E BRAF mutation associated
with CM (Pollock et al, 2003; Shain et al, 2015). Mutations in
BRAF are found in about 66% of CM while 83–95% of UM carry a
mutation in either the GNAQ or GNA11 gene (Davies et al, 2002;
Van Raamsdonk et al, 2008, 2010). Although MAPK (mitogen-
activated protein kinase) signalling is activated by the BRAF V600E
mutation, the oncogenic effect of GNAQ/11 is still to be defined.
A recent publication showed that MAPK activation has a minimal
role in the oncogenic potential of GNAQ mutations (Mouti et al,
2016); however, a central role has been attributed to the YAP/
Hippo pathway. YAP (Yes-associated protein) has not only a role
in homoeostasis and organ size during stress, but also in cancer
several oncogenes and tumour suppressor genes converge on YAP
(Overholtzer et al, 2006). In a sparse cell environment, YAP is
expressed in cell nuclei-promoting gene expression. Conversely, in
a dense cell environment, YAP is maintained in the cytoplasm and
inhibits cell growth. Overall, tissue growth is controlled through
the inhibition of YAP and its co-factors. Yu et al showed that
GNAQ/11 mutant activity is controlled by YAP activation (nuclear
YAP expression) in several UM cell lines (Yu et al, 2014, 2015).
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In this study, we analysed the frequency of GNAQ/11 mutations in
choroidal nevi and analysed YAP activation as a possible
downstream effect.
MATERIALS AND METHODS
From post-mortem human eyes obtained from the Lions NSW Eye
Bank (with consent and Human Research Ethics Committee
approval), choroidal pigmented lesions were identified, dissected
and tissue was paraffin-embedded (Supplementary Materials and
Methods) Dermal nevus tissues were obtained from the nevus
biobank of the Department of Dermatology, Leiden University
Medical Centre.
DNA extraction from nevi. DNA was extracted from formalin-
fixed and paraffin-embedded tissue of 16 choroidal nevi using the
ReliaPrep FFPE gDNA Miniprep System (Promega Corp, Madison,
WI, USA), following the manufacturer’s instructions. For DNA
extraction from dermal nevi, 20 tissue sections of 25 mm per nevus
were used.
Digital PCR. GNAQ/11 mutations (GNAQ Q209L, GNAQ Q209P,
GNAQ R1830, GNA11 Q209L and GNA11 R183C) and the BRAF
(V600E) mutation were analysed in choroidal nevi and dermal nevi
using digital PCR (Versluis et al, 2015). For copy number analysis
of chromosome 3 and 8q, essays for PPARG and PTK2 were used.
Proprietary probes and primers (Bio-Rad Laboratories, Inc.,
Hercules, CA, USA) were used.
Immunohistochemistry. Immunohistochemistry was performed
on paraffin sections of 15 choroidal nevi using the Ventana
Benchmark Ultra automated staining system (Ventana Medical
Systems Inc, Tuscon, AZ, USA), following the protocol described
previously (van Essen et al, 2014). Anti-Melan-A antibody (Ventana,
790-2290), YAP antibody (Cell Signalling Technology #4912) and
the BAP1 antibody (Santa Cruz, SC-28383, Dallas, TX, USA) were
used as primary antibodies. The UltraView Universal Alkaline
Phosphatase Red detection kit, (Ventana Ref.: 760-501) was used in
combination with target amplification (Ventana ref.: 760-080). The
slides were counterstained with haematoxylin II for 8min, followed
by an additional counterstaining with blueing reagent (Ventana
medical systems Inc.). Due to red chromogen staining on thin tissue
slides, we were able to detect positive staining in pigmented cells.
See also Supplementary Materials and Methods.
RESULTS
In the current study, 16 nevi from 13 post-mortem eyes of 12
donors were analysed for GNAQ/11 hotspot mutations. One pair of
donor eyes presented nevi in both the right and the left eye (nevi
11A-C), with the left eye containing two nevi (nevi 11A-B). Two
other eyes also contained two nevi (nevi 6 and 12) (Table 1).
Droplet digital PCR showed that 15 of the 16 choroidal nevi
presented one out of the three GNAQ/11 hotspot mutations
(Table 1). Mutations in GNAQ and GNA11 were distributed
equally in this cohort, similar to our observations in UM (Versluis
et al, 2015). None of the nevi showed evidence of multiple
mutations. Nevus 12B did not carry either of the GNAQ/11 hotspot
mutations. Different nevi from the same eye (nevi 6A-B, 11A-B
and 12A-B) never shared the same hotspot mutation. The nevus
from the right eye (nevus 11C) of the donor who had nevi in both
eyes contained the same mutation as one of the nevi in the left eye
(nevus 11B) (Table 1). The fraction of mutated nevus cells varied
from 1–55% with a median of 13%. Immunostaining revealed that
over 95% of the cells in 12 nevi were Melan-A positive (Table 1),
indicating that the tissue examined represented primarily nevus
cells with some stromal cells (Supplementary Figure 1B). Four nevi
could not be determined for Melan-A due to lack of material.
We examined tissues for the presence of chromosome
aberrations as potential progression markers and as the absence
of BAP1 is correlated with monosomy 3 in UM, we also performed
immunohistochemistry for BAP1 as another progression marker.
(van Essen et al, 2014) Neither gain of chromosome 8q/
chromosome 6p nor loss of chromosome 3 was observed in the
three nevi with the highest mutation fraction (nevi 11A-C) (not
shown). The eight nevi stained for BAP1 showed no loss of BAP1
expression (Table 1).
We determined the presence of GNAQ/11 and BRAF mutations
in dermal cutaneous nevi (n¼ 5) as a control. None of which
contained a GNAQ/11 hotspot mutation; instead, four out of five
dermal nevi harboured the BRAF V600E mutation with a median
mutant fraction of 45%. The mutant fraction of dermal nevi is in
marked contrast with the 13% GNAQ/11 mutant cells in choroidal
nevi and emphasises potential differences between BRAF and
GNAQ/11-driven nevus development. This suggests besides that
either other genetic factors are involved or that GNAQ/11 mutant
clones can also drive the proliferation of the wild-type melanocytes
in the nevus. The latter mechanism could be explained by YAP
activation initiated by GNAQ/11-mutated cells, which could
stimulate wild-type cells to proliferate.
We found heterogeneous YAP nuclear immunostaining in 14 out
of 15 choroidal nevi, with no cytoplasmic staining (Table 1 and
Figure 1). Although YAP staining tended to be more abundant in
nevi with a high mutant fraction, there was no significant correlation
between the percentage of positive YAP cells and the mutant cell
fraction (Table 1, P¼ 0.334, Spearman correlation coefficient).
In the only nevus (12B) without a GNAQ/11 mutation, positive
YAP expression in nuclei was also detected. This indicates that
YAP activation may occur independently of the presence of a
GNAQ/11 mutation. Normal choroidal melanocytes were negative
for YAP staining, as was retinal tissue. Sporadically a retinal
pigment epithelium cell was found with positive YAP staining
(Figure 2).
DISCUSSION
As hypothesised, human choroidal nevi did harbour a GNAQ/11
mutation. No other mutations were found, which suggests that
those mutations are clonal. The low GNAQ/11 mutant fraction in








Figure 1. Clinical and histopathological manifestation of a choroidal
nevus. (A) Choroidal nevus (N) (72 year old, female). Retina and RPE
removed; choroidal vessels visible (asterisk). Size B4mm diameter.
(B) Section through nevus showed thickened area of pigmented nevus
cells and large blood vessels at the lesion’s edge (arrows) (periodic
acid–Schiff stain).
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oncogene function that may be explained by aberrant YAP
signalling in choroidal nevi. The oncogenic potential of YAP is
broadly recognised and high levels of YAP expression in the
nucleus have been associated with several malignancies
(Overholtzer et al, 2006). Yu et al (2014) described a positive
correlation between mutant GNAQ/11 and aberrant YAP activa-
tion (nuclear expression) in UM cell lines. In our study, the nevi
with a GNAQ/11 mutation all showed nuclear YAP, confirming
this positive correlation between mutant GNAQ/11 and YAP
activation. However, this correlation was not significant. Moreover,
the one nevus without GNAQ/11 mutations still possessed YAP
activity in the nucleus. This is in accordance with the results of Yu
et al who also found evidence of nuclear YAP activity in wild-type
UM cell lines (Mel285 and Mel290), suggesting that YAP
activation is not solely dependent on GNAQ/11 mutations, and
that other factors may contribute to YAP activity (Yu et al, 2014).
In summary, we found that GNAQ/11 mutant clones make up a
fraction of the cells in choroidal nevi. Nevus cells are furthermore
characterised by heterogeneous YAP expression. Combined
GNAQ/11 and YAP may constitute a putative precursor tumour
pathway with an activated oncogene (GNAQ/11) and downstream
effector (YAP).
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Table 1. Molecular analysis of choroidal nevus






Q209La Mutant cellsb (%) YAP-positive cellsc (%) Melan-Ad BAP1e
1 F, 90 þ 10 ND ND ND
2 F, 79 þ 1.1 1.8 495% Positive ND
3 F, 62 þ 14 6.6 495% Positive ND
4 F, 73 þ 3 33.1 495% Positive Positive
5 F, 87 þ 5.8 0 495% Positive ND
f6A F, 86 þ 16 27.9 495% Positive ND
6B F, 86 þ 6.6 44.1 ND ND
7 F, 59 þ 6.2 23.2 ND ND
8 M, 59 þ 12 56.4 495% Positive Positive
9 M, 59 þ 17 0.4 ND ND
10 F, 80 þ 5.8 47 495% Positive Positive
f11A M, 54 þ 40 18.6 495% Positive Positive
11B M, 54 þ 36 48.2 495% Positive Positive
g11C M, 54 þ 55 81.1 495% Positive Positive
f12A F, 77 þ 13 68.5 495% Positive Positive
12B F, 77 0 22.0 495% Positive Positive
Abbreviation: ND, not to be determined.
aGNAQ/11 mutations.
bMutant cells: fraction of cells containing a hotspot mutation.
cPercentage of cells positive for YAP staining per nevus.
dMelan-A: 11 nevi stained positive for Melan-A (Supplementary Figure 1B). In four nevi, expression could ND due to limited material.
eBAP1: eight nevi stained positive for BAP1. Eight nevi could not be determined due to limited material.
fTwo nevi detected in one eye indicated by A and B







Figure 2. YAP staining in human choroidal nevi. (A) Nevus 2 with an average of 1.8% YAP-positive cells. A nevus cell with a negative, blue nucleus
is seen (white arrow). Magnification of objective 40. (B) Nevus 12A with an average of 13% YAP-positive cells. Yapþ nuclei in nevus cells are
visible (pink, white arrows). A rare RPE cell is found with nuclear YAP staining (blue arrow). Magnification of objective  40. BM¼Bruch’s
membrane; cc¼ choriocapillaris; rpe¼ retina pigment epithelium.
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